Optimizing Cardiac Delivery of Modified mRNA
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Modified mRNA (modRNA) is a new technology in the field of somatic gene transfer that has been used for the delivery of genes into different tissues, including the heart. Our group and others have shown that modRNAs injected into the heart are robustly translated into the encoded protein and can potentially improve outcome in heart injury models. However, the optimal compositions of the modRNA and the reagents necessary to achieve optimal expression in the heart have not been characterized yet. In this study, our aim was to elucidate those parameters by testing different nucleotide modifications, modRNA doses, and transfection reagents both in vitro and in vivo in cardiac cells and tissue. Our results indicate that optimal cardiac delivery of modRNA is with N1-Methylpseudouridine-5′-Triphosphate nucleotide modification and achieved using 0.013 μg modRNA/mm 2 /500 cardiomyocytes (CMs) transfected with positively charged transfection reagent in vitro and 100 μg/mouse heart (1.6 μg modRNA/μL in 60 μL total) sucrose-citrate buffer in vivo. We have optimized the conditions for cardiac delivery of modRNA in vitro and in vivo. Using the described methods and conditions may allow for successful gene delivery using modRNA in various models of cardiovascular disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Direct Gene Transfer into Mouse Muscle in Vivo
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173
Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930 · cited 2×
“This is mostly due to mRNA activation of the innate immune response via stimulation of Toll-like receptors (TLRs).11, 12 In addition, mRNA is prone to cleavage by RNase when delivered in vivo.11, 13, 14 Kariko et al.14 showed that modified mRNA (modRNA), produced by the replacement of uridine with pseudouridine, resul…”
BackgroundHuman cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population
Yang, L., Soonpaa, M. H., Adler, E. D., Roepke, T. K., Kattman, S. J., Kennedy, M., Henckaerts, E., Bonham, K., Abbott, G. W., Linden, R. M., et al. (2008) · Nature · doi:10.1038/nature06894 · Cited by 1,389 · cited 1×
“hPSC Differentiation The hPSCs (H9) were differentiated along a cardiac lineage as previously described.(37) Briefly, hPSCs were maintained in E8 media and”
MethodPardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
Wang, G., McCain, M. L., Yang, L., He, A., Pasqualini, F. S., Agarwal, A., Yuan, H., Jiang, D., Zhang, D., Zangi, L., et al. (2014) · Nature Medicine · doi:10.1038/nm.3545 · Cited by 837
Self-citationExpression of therapeutic proteins after delivery of chemically modified mRNA in mice
Kormann, M. S. D., Hasenpusch, G., Aneja, M. K., Nica, G., Flemmer, A. W., Herber-Jonat, S., Huppmann, M., Mays, L. E., Illenyi, M., Schams, A., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1733 · Cited by 733
Andries, O., Mc Cafferty, S., De Smedt, S. C., Weiss, R., Sanders, N. N., & Kitada, T. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.051 · Cited by 701 · cited 1×
“These findings are aligned with the data from other laboratories 26 showing that 1-mcU-incorporated mRNA outperforms cU-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and after intradermal or intramuscular injections in mice.(25)”
ResultZangi, L., Lui, K. O., von Gise, A., Ma, Q., Ebina, W., Ptaszek, L. M., Später, D., Xu, H., Tabebordbar, M., Gorbatov, R., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2682 · Cited by 646
Self-citationReversal of Diabetes Insipidus in Brattleboro Rats: Intrahypothalamic Injection of Vasopressin mRNA
Jirikowski, G. F., Sanna, P. P., Maciejewski-Lenoir, D., & Bloom, F. E. (1992) · Science · doi:10.1126/science.1546298 · Cited by 282
Cited by
Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery
Kowalski, P. S., Rudra, A., Miao, L., & Anderson, D. G. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.012 · Cited by 1,127
“103,104 This study suggests that complexation of the mRNA may potentially hinder translation in cardiac tissue and increase the apoptosis of cardiac cells in vivo .”
Opportunities and Challenges in the Delivery of mRNA-Based Vaccines
Wadhwa, A., Aljabbari, A., Lokras, A., Foged, C., & Thakur, A. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020102 · Cited by 584
“Interestingly, more efficient translation has at times been measured when compared to mRNA‐loaded nanoparticle‐based delivery systems [90,93].”
BackgroundPkm2 Regulates Cardiomyocyte Cell Cycle and Promotes Cardiac Regeneration
Magadum, A., Singh, N., Kurian, A. A., Munir, I., Mehmood, T., Brown, K., Sharkar, M. T. K., Chepurko, E., Sassi, Y., Oh, J. G., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.043067 · Cited by 286
Self-citationCarlsson, L., Clarke, J. C., Yen, C., Gregoire, F., Albery, T., Billger, M., Egnell, A.-C., Gan, L.-M., Jennbacken, K., Johansson, E., et al. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.04.003 · Cited by 178
“More recent studies withmRNAhave used a combination of liposomal delivery mechanisms as well as non-toxic buffers.(7,11,28,39,40) Based on these in vivo RNA studies, we screened for transfection and protein expression efficiency inmultiple organs usingmRNA in a citrate-saline buffer.”
BackgroundMethodResultInfluentialmRNA-Based Protein Replacement Therapy for the Heart
Magadum, A., Kaur, K., & Zangi, L. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2018.11.018 · Cited by 176
Self-citation
Metadata
- Authors
- Sultana, N., Magadum, A., Hadas, Y., Kondrat, J., Singh, N., Youssef, E., Calderon, D., Chepurko, E., Dubois, N., Hajjar, R. J., & Zangi, L.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2017-06
- Volume
- 25
- Issue
- 6
- Pages
- 1306-1315
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2602505141
- Cited by
- 112
- References
- 10
- FWCI
- 3.69
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.